Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer

Video

In Partnership With:

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Related Videos
Ibrahim Aldoss, MD
Minoo Battiwalla, MD
Arlene O. Siefker-Radtke, MD
Heinz-Josef Lenz, MD, FACP
Robert Wang, MD, of Fox Chase Cancer Center
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Changchun Deng, MD, PhD, associate professor, hematology/oncology, University Hospitals Seidman Cancer Center; member, Immune Oncology Program, Case Comprehensive Cancer Center
Jaime R. Merchán, MD
Erin Frances Cobain, MD
Related Content
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 6th 2024
Article
Jack Khouri, MD

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

November 9th 2023
Podcast
Samer A. Srour, MB ChB, MS

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article